De réir Jabbar et al. De chuid Ollscoil Gothenburg sa tSualainn, is féidir le mais-speictriméadracht spriocdhírithe atá bunaithe ar thrí bhithmharcóir de shreabhán chisteach a aithint agus a mheas go han-chruinn an fhéidearthacht go cysts pancreatic ag forbairt isteach ailse pancreatic . Is fiú staidéir eile a dhéanamh chun a dhearbhú an féidir leis an modh turgnamhach seo cabhrú le diagnóis ailse in am, idirghabháil rathúil a dhéanamh agus ailse a chosc. (J Clin Oncol. leagan ar líne 22 Samhain, 2017)
Cystic lesions of the pancreas are very common in imaging, and about half are ailse pancreatic lesions. Therefore, accurate and specific diagnosis is essential for the correct treatment of patients. Unfortunately, the currently used diagnostic methods cannot effectively distinguish between pancreatic precancerous lesions and malignant pancreatic cystic lesions.
Bhain na taighdeoirí úsáid as samplaí sreabhán cisteach a fuarthas trí thonncadh faoi threoir an ionscópachta ultrafhuaime traidisiúnta le haghaidh anailíse. I staidéar cohóirt ar 24 othar, d’aithin modh taiscéalaíoch na bitheolaíochta próitéine 8 mbithmharcóir iarrthóra a d’fhéadfadh faisnéis a sholáthar maidir le claochlú urchóideach agus dysplasia ardghrád / athruithe ailse. Ina dhiaidh sin, rinneadh anailís chainníochtúil ar 30 peptide lipéadaithe agus mais-speictriméadracht monatóireachta imoibriúcháin comhthreomhar ar 80 othar sa tacar sonraí agus ar 68 othar sa tacar fíoraithe. Ba é críochphointe an staidéir mar thoradh ar dhiagnóis paiteolaíochta máinliachta nó le leanúint cliniciúil.
The results show that the best markers for malignant tumors may be a group of peptides derived from MUC-5AC and MUC-2. These markers can identify precancerous lesions / malignant lesions from benign lesions. The accuracy is as high as 97%. Compared with the cystic liquid carcinoembryonic antigen and cytological detection of these standard identification methods, the accuracy of these standard methods is 61% (95% CI 46% ~ 74%, P <0.001) and 84% (95% CI 71% ~ 92%, P = 0.02). MUC-5AC combined with prostate stem cell antigen can identify high-grade dysplasia or cancer, with an accuracy of 96%, can detect 95% of malignant lesions or severe dysplasia, and the detection rate of carcinoembryonic antigen and cytology 35% and 50% respectively (P <0.001, P = 0.003).
